KPV Peptide Dosage: What the Evidence Shows

There is no established KPV peptide dosage for people. In its review for the July 2026 advisory committee meeting, the US Food and Drug Administration (FDA) found no clinical studies or human exposure data for KPV by any route, so no trial has tested what amount is effective or safe. Specific human dosing figures promoted online are not supported by the human clinical studies identified in FDA's review.

Key takeaways

• No established human dose: FDA identified no human clinical pharmacokinetic, pharmacodynamic or safety studies for KPV free base or KPV acetate in its review.
• Animal and cell data only: Mouse colitis studies used KPV in drinking water or packed into nanoparticles, and those amounts do not convert to a human dose.
• Narrow federal policy: An October 2026 HHS interim policy provides enforcement discretion for qualifying prescription compounding of single-ingredient KPV acetate in oral and topical forms. It does not approve KPV or establish a dose.
• Vial math is not a dose: Concentration math tells you what a label contains, not what amount is safe.

What is KPV?

KPV is a three-amino-acid peptide (lysine-proline-valine) that matches the tail end of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone involved in inflammation signaling. Laboratory studies describe KPV as anti-inflammatory: in cell experiments, nanomolar concentrations reduced activity of NF-kB, a key inflammation switch, and KPV entered gut and immune cells through a transporter called PepT1 (Dalmasso et al., Gastroenterology, 2008). For how KPV compares with other compounds studied for inflammation, see our list of anti-inflammatory peptides.

Is there a recommended KPV dose?

No. A recommended dose normally comes from human studies that measure how a drug is absorbed, how long it lasts and which amounts cause side effects. FDA's evaluation of KPV for the July 2026 Pharmacy Compounding Advisory Committee (PCAC) states that the agency did not identify clinical studies in humans assessing the pharmacokinetics of KPV via any route, and did not identify any clinical studies or human exposure data at all. FDA concluded that potential safety risks of KPV in humans are unknown (FDA KPV evaluation for PCAC).

The same review found no published studies of compounded or non-compounded KPV products used in humans, and noted that outsourcing facilities reported no KPV products from 2017 through June 2025. Any specific microgram or milligram figure presented as "the" KPV dose is therefore an unverified convention, not a tested amount.

Where do the KPV dosages online come from?

They come from sellers, telehealth clinics and user communities. FDA's review found websites promoting KPV as injectable, oral, topical and nasal spray products, alone and in multi-ingredient combinations with peptides such as BPC-157 and TB-500. Those sites make claims ranging from gut health to wound healing, but FDA found no human clinical evidence behind them. A protocol repeated across many sites is still a protocol no one has tested in a trial.

The only product strength named in the original compounding nomination was a 0.1% cream or gel for topical use. That figure describes a proposed product, not a dose shown to be safe or effective.

What KPV amounts and concentrations were studied in animals?

KPV research comes from cell cultures and mice, and the amounts depend heavily on how the peptide was delivered:

• Drinking water in mice: In two mouse models of colitis, KPV given in drinking water reduced inflammation markers (Dalmasso et al., 2008).
• Nanoparticles in mice: When KPV was packed into colon-targeted nanoparticles, it worked in mice at a concentration about 12,000-fold lower than free KPV in solution (Laroui et al., Gastroenterology, 2010).
• Skin models: FDA cites an in vitro study in which KPV did not pass through human cadaver skin unless the skin barrier was broken with methods such as microneedles or iontophoresis.

The 12,000-fold difference illustrates how strongly KPV delivery and experimental concentration depend on formulation. These were preclinical findings, not a human dose-finding study. Neither the mouse experiments nor the cell studies establish a safe, effective or recommended dose for people.

Oral vs topical vs injectable KPV

Route	What the evidence shows	Status under the 2026 HHS policy
Oral	Mouse colitis studies only; no human absorption data	Within the interim policy's scope for KPV acetate, subject to its conditions, including documentation of adequate oral bioavailability for the specific formulation in humans
Topical	Cadaver-skin study showed little penetration through intact skin	Covered for compounding of KPV acetate
Injectable	No human data	Not covered
Nasal	No human data	Not covered

What did the 2026 FDA and HHS decisions change?

FDA's review recommended against adding KPV to the list of bulk substances pharmacies may use for compounding. The PCAC voted in favor of inclusion at its July 2026 meeting, and an HHS interim enforcement-discretion policy announced in October 2026 then listed KPV among six peptides, with BPC-157, Epitalon, MOTS-c, Semax and TB-500 (HHS peptide enforcement-discretion policy).

For KPV, HHS's interim enforcement-discretion policy applies to KPV acetate in topical and oral dosage forms, subject to specified conditions. Qualifying products must be compounded by an eligible state-licensed pharmacy, federal facility or licensed physician under a patient-specific prescription, using appropriately characterized ingredients with a valid certificate of analysis. Each compounded product may contain only one active pharmaceutical ingredient listed in the policy. For oral products, the compounder is expected to document adequate human bioavailability for the specific formulation. The policy also includes product-quality and adverse-event reporting conditions. It does not cover injectable or nasal KPV, grant FDA approval, or establish a safe or effective dose. For the parallel decisions on a related peptide, see our BPC-157 FDA approval status guide.

How much KPV is in KLOW?

A standard 80 mg KLOW blend vial is labeled with 10 mg of KPV alongside GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg. Because KLOW combines four peptides, it falls outside the HHS single-ingredient condition. Our KLOW peptide dosage guide covers the blend's label math in detail.

How to read a KPV vial label

KPV vial labels may state the total amount of peptide in milligrams (mg), but that figure is not a recommended dose. Concentration describes how much material is present per unit of volume; it does not establish a safe or effective amount for a person.

A vial labeled 10 mg contains a claimed total quantity of 10 mg of peptide. The label alone does not verify the substance's identity, purity, potency or suitability for human use. FDA has also identified different salts and derivatives marketed under the name KPV, making the precise chemical identity important.

For general laboratory concentration calculations, see our bacteriostatic water calculator. These calculations are not clinical dosing instructions and do not validate any route of administration.

How long does KPV last after reconstitution?

The reviewed sources do not establish a validated shelf life for reconstituted KPV. FDA also noted that peptides as short as two amino acids can clump together (aggregate), which can change how a product behaves. General storage guidance for mixed peptides is covered in our guide to how long reconstituted peptides last.

What are the side effects of KPV?

They are unknown. FDA's search of its adverse event database through December 3, 2025 retrieved no KPV reports, and the literature search found no case reports. That absence reflects missing data, not proof of safety: FDA notes that compounders under section 503A generally do not report adverse events. FDA also found no toxicity, genotoxicity, reproductive or cancer studies, and said it could not rule out immune reactions to the peptide.

Seek emergency care right away for signs of a severe allergic reaction (anaphylaxis), such as trouble breathing, swelling of the face, lips or throat, widespread hives, or fainting (MedlinePlus: anaphylaxis). Problems with a compounded product can be reported to FDA MedWatch.

Frequently asked questions

Is KPV FDA approved?

No. KPV is not an FDA-approved drug. The October 2026 HHS policy only means federal authorities do not intend to take enforcement action against qualifying prescription compounding of oral or topical KPV acetate while FDA completes rulemaking.

Can KPV be taken orally?

Oral KPV reduced colitis in mice, and the HHS policy covers oral compounded KPV acetate. No study has measured how much oral KPV a person absorbs, which is why HHS expects compounders to document adequate oral bioavailability in humans.

Is injectable KPV covered by the HHS policy?

No. For KPV, the policy covers topical and oral dosage forms only.

What is a typical KPV cycle length?

No study has defined a cycle length for KPV in people. Cycle lengths posted online are conventions, not tested schedules.

About this article: PeptideStack is an affiliate publisher. The Peptide Partners card on this page is a paid referral offer and is not medical guidance or a recommendation to use KPV. This article is educational and not medical advice; talk to a licensed clinician about any treatment decision.